Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

2005/04/01 by Hannah Farmer, Nuala McCabe, Christopher J. Lord +14 · 36 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #DNA Repair Mechanisms #PARP inhibition in cancer therapy #CRISPR and Genetic Engineering

paper · doi:10.1038/nature03445

Cited by

• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
• Clonal Hematopoiesis and Its Impact on Human Health
• The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
• A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
• Base excision repair and its implications to cancer therapy
• Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors
• RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant Tumors
• Strategies to design clinical studies to identify predictive biomarkers in cancer research
• Targeting DNA damage repair pathways in pancreas cancer
• Homologous Recombination and Replication Fork Protection: BRCA2 and More!
• Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
• The Hallmarks of Predictive Oncology
• AURKA inhibitor VIC-1911 induces mitotic defects and functional BRCAness, sensitizing prostate cancer to PARP inhibition
• ATM safeguards DNA replication at endogenous base lesions
• Context-dependent genetic interactions in cancer
• RAD51-mediated homologous recombination is a pro-tumour driver pathway
• BaCoN (Balanced Correlation Network) improves prediction of gene buffering
• Biological and clinical significance of PARP1 protein expression in breast cancer
• DNA shape and epigenomics distinguish the mechanistic origin of human genomic structural variations
• CRISPR knockout genome-wide screens identify the HELQ-RAD52 axis in regulating the repair of cisplatin-induced single-stranded DNA gaps
• PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification
• The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma
• Genome-wide CRISPR screens identify the EXO1-CAF-1 pathway suppressing R-loop-associated DNA damage
• Radiation-Induced Skin Fibrosis
• Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer
• PARPs and ADP-ribosyl hydrolases in cancer therapy: From drug targets to biomarkers
• Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
• Computationally-designed aptamers targeting RAD51-BRCA2 interaction impair homologous recombination and induce synthetic lethality
• Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
• A decade of clinical development of PARP inhibitors in perspective
• 5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells
• The influence of homologous recombination repair on temozolomide chemosensitivity in gliomas
• Genomic instability, inflammatory signaling and response to cancer immunotherapy
• PARPs and PARP inhibitors: molecular mechanisms and clinical applications
• Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix
• Palacio de Congresos de Ibiza